Clinical Trials on Fibrous Dysplasia, Polyostotic in France

Total 827 results

Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada, France, Spain, Israel, Australia, Austria
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

United States, France, United Kingdom, Germany, Spain, Belgium, Canada, Australia, Netherlands, Denmark, Czech Republic, Italy, Austria, Ireland, Sweden
Insmed Incorporated

Completed

Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Cystic Fibrosis

France, Poland, United Kingdom, Germany, Spain, Belgium, Bulgaria, Serbia, Denmark, Greece, Netherlands, Hungary, Ireland, Slovakia, Canada, Italy, Austria
Sanofi

Terminated

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver (SPARe-2)

Liver Cirrhosis | Ascites

France, Canada, Brazil, Poland, Romania, Russian Federation, Australia, Germany, Spain, Turkey, Bulgaria, Malaysia, Serbia, Singapore, Belgium, Czech Republic, Mexico, Chile, United States, Argentina, Bosnia and Herzegovina
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
University of Massachusetts, Worcester
Cystic Fibrosis Foundation

Completed

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis (DHA)

Cystic Fibrosis

United States
Genentech, Inc.

Completed

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
PTC Therapeutics
Cystic Fibrosis Foundation

Completed

Study of Ataluren (PTC124™) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, United Kingdom, Spain, Canada, Germany, Israel, Italy, Netherlands, Sweden
Boehringer Ingelheim

Completed

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, France, Germany, Italy, Netherlands, New Zealand, Portugal, Russian Federation, United Kingdom
Sanofi

Terminated

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver (SPARe-1)

Liver Cirrhosis | Ascites

France, Canada, Romania, Australia, Germany, Italy, Portugal, Spain, Bulgaria, Malaysia, Serbia, Singapore, Taiwan, Belgium, Czech Republic, Croatia, Hungary, Israel, United Kingdom, Korea, Republic of, South Africa, United States, ... and more
University Hospital, Bordeaux

Recruiting

Functional Tests to Resolve Unsolved Rare Diseases. Rares. (RID)

Intellectual Disability | Cystic Fibrosis | Neurodegeneration With Brain Iron Accumulation (NBIA) | Congenital Heart Defect | Albinism | Rubinstein-Taybi Syndrome | Periventricular Nodular Heterotopia

France
Gilead Sciences
Covance; ClinPhone, Inc.; Chiltern International Inc.

Completed

Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa

Cystic Fibrosis

Belgium, France, Germany, Italy, Netherlands, Spain, United States, Ireland, United Kingdom, Portugal, Austria, Denmark, Switzerland
Centre Hospitalier Universitaire de Besancon

Active, not recruiting

"Early TIPS" Versus Glue Obliteration to Prevent Rebleeding From Gastric Varices (GAVAPROSEC)

Cirrhosis | Bleeding Gastric Varices

France
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis

United States, Hungary, Israel, South Africa, Spain
Pharmaxis
ethica Clinical Research Inc.; Europe: KasaConsult bvba, Hoegaarden, Belgium; Argentina: Resolution Latin America; Buenos Aires, Argentina

Completed

Long Term Administration of Inhaled Mannitol in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Canada, Argentina, Germany, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Australia, Denmark, Canada, Sweden
Southwest Oncology Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Terminated

S9624 Ifosfamide in Treating Patients With Meningeal Tumors

Chondrosarcoma | Adult Rhabdomyosarcoma | Adult Fibrosarcoma | Adult Leiomyosarcoma | Adult Malignant Meningioma | Adult Brain Malignant Hemangiopericytoma

United States, Australia, Peru, Puerto Rico
AstraZeneca

Completed

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (PROXYMO-ADV)

Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

United States, Austria, Italy, Thailand, Germany, Korea, Republic of, Japan, Malaysia, New Zealand, Spain, Taiwan, Turkey, Australia, Israel, Argentina, Canada, Greece, South Africa, United Kingdom, France
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Genentech, Inc.

Recruiting

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Idiopathic Pulmonary Fibrosis | Systemic Sclerosis With Lung Involvement

United States, Korea, Republic of, Taiwan, Australia, Spain, Italy, Israel, Belgium, Argentina, France, Brazil, Greece, Poland, Chile, South Africa, Canada, New Zealand
Gilead Sciences

Completed

Safety of AZLI in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa in the Lower Airways (PALS)

Cystic Fibrosis | Pseudomonas Aeruginosa

Spain, United States, Germany, France, Italy, Poland
Anthera Pharmaceuticals

Completed

SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis (SIMPLICITY)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of Tezacaftor (VX-661) in Combination With Ivacaftor (VX-770) in Subjects Aged 12 Years and Older With Cystic Fibrosis (CF), Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor

Cystic Fibrosis

United States, Australia, Canada, United Kingdom, Germany, Belgium, Austria, Ireland, Italy, France
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
Bayer
Novartis

Completed

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Germany, Canada, Australia, Sweden, Denmark, Norway, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Malabsorption Syndromes | Cystic Fibrosis | Steatorrhea | Exocrine Pancreatic Insufficiency

United States, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
University Hospital, Lille

Recruiting

Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease (COMADHAA)

Alcoholic Liver Disease | Severe Alcoholic Hepatitis | Alcoholic Cirrhosis

France
University of Sao Paulo
Federal University of Rio Grande do Sul; University of Campinas, Brazil; Hospital... and other collaborators

Unknown

Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis

Acute Kidney Injury | Hepatorenal Syndrome

Brazil
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients (TIS)

Cystic Fibrosis

United States, Ireland, United Kingdom, France, Germany, Israel
Seattle Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center

Completed

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH)

Cystic Fibrosis

United States
PTC Therapeutics

Terminated

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Cystic Fibrosis

United States, Spain, France, Belgium, United Kingdom, Australia, Brazil, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Argentina, Greece
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
AbbVie

Completed

A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222

Cystic Fibrosis

United States, Belgium, Canada, Czechia, France, Hungary, Netherlands, New Zealand, Poland, Slovakia, United Kingdom, Serbia
Womed

Active, not recruiting

PREvention of Intrauterine Adhesion After Adhesiolysis With Novel Tri-block deGradable Polymer Film. (PREG2)

Asherman Syndrome | Intrauterine Adhesion

Switzerland, Spain, France, China, Belgium, Czechia, Italy
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Celtaxsys, Inc.

Completed

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Cystic Fibrosis

United States, United Kingdom, Canada, Belgium, France, Germany, Italy
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Bristol-Myers Squibb

Terminated

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Germany, Taiwan, United Kingdom, Spain, Argentina, Brazil, France, Israel, Italy, Japan, Korea, Republic of, Belgium, Canada, Puerto Rico, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Bristol-Myers Squibb

Completed

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (FALCON 1)

Nonalcoholic Steatohepatitis | Liver Fibrosis | Nonalcoholic Fatty Liver Disease (NAFLD)

United States, Japan
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Boehringer Ingelheim

Terminated

A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly

Liver Cirrhosis | Hypertension, Portal

Spain, Germany, Canada, China, Austria, United States, Japan, France, Korea, Republic of, Romania
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States

Clinical Trials on Fibrous Dysplasia, Polyostotic in France

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations